Pivekimab sunirine
IMGN632
FILED
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Peak Sales Est$500M
Formulations[]
Mechanism: CD123-targeting ADC
Expert: Antibody-drug conjugate targeting CD123 (IL-3 receptor alpha) for BPDCN and AML.
Everyday: A targeted drug that delivers chemotherapy to rare blood cancer cells.
Targets: ["CD123"]
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| BPDCN | FILED | Ph1/2 BPDCN | [] |
Upcoming Catalysts (1)
Pivekimab Sunirine - BPDCN - FDA Approval
2026
Notes
CD123-targeting ADC for BPDCN. Breakthrough therapy designation. Acquired from ImmunoGen.
Data from Supabase · Updated 2026-03-24